Aridis Pharmaceuticals Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview - Completed an initial public offering on August 16 and began trading on the Nasdaq Capital Market Tue, 13 Nov 2018 07:30:00 -0500 Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine" - Positive safety and efficacy trends of AR-301 in Phase 1/2a clinical trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine Wed, 07 Nov 2018 07:30:00 -0500 Aridis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference Wed, 26 Sep 2018 08:30:00 -0400 Aridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product Candidates - New patents add to previously issued U.S. and international counterpart patents and patent applications that form Aridis's fully human monoclonal antibody patent portfolio Mon, 24 Sep 2018 07:00:00 -0400 Aridis Pharmaceuticals Announces Pricing of Initial Public Offering Mon, 13 Aug 2018 19:31:00 -0400